Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial
Edmund J Lewis,Julia B Lewis,Tom Greene,Lawrence G Hunsicker,Tomas Berl,Marc A Pohl,Dick de Zeeuw,Hiddo Lambers Heerspink,Richard D Rohde,Robert C Atkins,Anne T Reutens,David K Packham,Itamar Raz,Collaborative Study Group,Peter Kerr,Paul J Champion de Crespigny,Robyn Langham,Bruce Jackson,George Jerums,Michael d'Emden,David Packham,Simon Roger,Dennis Yue,Jeff Karrasch,Nicole Isbel,Mark Thomas,Richard Simpson,Rick Cutfield,Paul L Drury,Patrick Manning,Rudolf Prager,Guntram Schernthaner,Wendy Engelen,Gert Meeus,Wim Van Biesen,Luc Van Gaal,Lars Bo Johansen,Hans-Henrik Lervang,Sten Madsbad,Elisabeth Mathiesen,Hans Perrild,Aage Prange,Peter Rossing,Gudrun Steffensen,Birger Thorsteinsson,Søren Urhammer,Henrik Vestergaard,Pierre Bataille,Bernadette Faller,Michel Godin,Aurelie Meurette,Odile Verier Mine,Philippe Zaoui,Laszlo Gero,Gyorgy Jermendy,Judit Nagy,Aniko Somogyi,Gyula Tamas,Gyozo Vandorfi,Peter Voros,Gabor Winkler,Faiad Adawi,Sydney Benchetrit,Yosef Cohen,Ilana Harman Boehm,Avraham Herskovitz,Eddy Karnieli,Batya Kristal,David van Dijk,Julio Wainstein,Yoram Yagil,Yair Yerushalmi,Alberto Albertazzi,Roberto Bigazzi,Roberto Boero,Enzo Bonora,Andrea Corsi,Antonio Dal Canton,Giacomo DeFerrari,Stefano Del Prato,Paola Fioretto,Loreto Gesualdo,Fabio Malberti,Giuseppe Pugliese,Roberto Trevisan,Carmine Zoccali,Alessandro Zuccala,C B Brouwer,Jan Willem F Elte,Jan-Evert Heeg,Klaas Hoogenberg,Roel P L M Hoogma,Louis A G Lieverse,Bert-Jan Potter van Loon,Fred G E G M Storms,Rob M Valentijn,Jan van der Meulen,R P Verhoeven,A J J Woittiez-Almelo,Edward Franek,Maria Gorska,Danuta Pupek Musialik,Andrzej Wiecek,Joao Sequeira Duarte,Fernando de Alvaro Moreno,Enric Esmatjes Mompo,Maria Angeles Goicoechea,Manuel Gorostidi Perez,Jose Luis Gorriz Teruel,Xose Manuel Lens Neo,Jose M Pascual Izuel,Manuel Praga Gerente,Ramon Romero Gonzalez,Marti Vallés,Magnus Ekelund,Anders Frid,Per-Eric Lins,Jan Tencer,Rudy Bilous,Bernd Franke,John N Arbie,Mohamed Hassanein,Simon Heller,Sally Marshall,Ashraf Mikhail,Hilary Tindall,Jiten Vora,Peter Winocour,Gordon Roy Bailey,Dan Cattran,Michelle Hladunewich,Lawrence A Leiter,Stuart Allan Ross,Hugh D Tildesley,Vincent Woo,Robert Anderson,Stephen Aronoff,Bruce Barrer,Andrew Behnke,Stephen Bissette,Thomas Blevins,Samuel Blumenthal,Vardaman M Buckalew,Rafael Burgos Calderón,Vito Campese,Richard Cherlin,Joseph Chinn,Troy Dixon,Hugh Dúrense,Gilbert Eisner,Stephen Fadem,David Fitz-Patrick,Claude Galphin,Laurence Gavin,Ron Goldberg,G M Gollapudi,Simin Goral,Stephen Grubb,Robert R Henry,Kenneth Hershon,David Jonson,Roy Kaplan,Murray A Katz,William Kaye,Eric Klein,David Klonoff,Norman Kramer,Barton Levine,James Lohr,Maria F Lopes Virilla,Janet B McGill,James H Mersey,Robert Michaels,David Morin,Lyle Myers,John Pullman,Efrain Reisin,Raul Rodelas,Clive Rosendorff,Gerald Schulman,Allan B Schwartz,Sherwyn Schwartz,Jon Shapiro,Zeev Sharon,Marvin V Sinsakul,Ronald D Smith,Norman Soler,Richard Solomon,Danny Sugimoto,Jeannine Turner,Manuel Velásquez,Daniel Weiss,Thomas B Wiegmann,Mark E Williams,Jonathan Wise,Steven Yale,Bessie Young,Douglas Young,Steven Zeig,Leonard Zemel,Franklin J Zieve,William Zigrang,Jose L Cangiano
DOI: https://doi.org/10.1053/j.ajkd.2011.06.020
Abstract:Background: Sulodexide, a heterogenous group of sulfated glycosaminoglycans, includes low-molecular-weight heparin (~80% ± 8%), high-molecular-weight heparin (~5% ± 3%), and dermatan (~20% ± 8%), with a mean molecular weight of ~9 kDa. The drug is absorbed orally and has no anticoagulant effect in the doses used. Small preliminary studies consistently showed sulodexide to be associated with decreased albuminuria in patients with diabetes. Study design: We conducted a multicenter placebo-controlled double-blinded study to determine the effect of sulodexide on urine albumin excretion in patients with type 2 diabetic nephropathy. Setting & participants: Patients with type 2 diabetes and urine albumin-creatinine ratios (ACRs) of 35-200 mg/g in men and 45-200 mg/g in women were enrolled. Serum creatinine level was <1.5 mg/dL. Blood pressure goal was 130/80 mm Hg. A maximum US Food and Drug Administration-approved dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for a minimum of 4 months before randomization was required. Intervention: The study drug was sulodexide, 200 mg/d. Outcome & measurements: The primary end point was normoalbuminuria (ACR <20 mg/g and a decrease >25%) or 50% decrease in baseline ACR. Results: In 1,056 randomly assigned patients with a mean baseline ACR of 107.8 ± 83.7 mg/g, comparing the sulodexide versus placebo groups, the primary end point was achieved in 16.5% versus 18.4%; normoalbuminuria, in 7.9% versus 6.1%; and a 50% decrease in albuminuria, in 15.4% versus 17.6%. The relative probability of any given change in albuminuria was identical in both groups. Limitations: We were unable to determine whether the administered sulodexide was absorbed from the gastrointestinal tract. Conclusion: Sulodexide failed to decrease urine albumin excretion in patients with type 2 diabetic nephropathy and microalbuminuria.